Targeting the NLRP3 (nucleotide-binding oligomerisation domain-, leucine-rich repeat-, and pyrin domain-containing 3) inflammasome to modulate AD pathology has increasing interest as a therapeutic strategy [230], with emerging evidence of A2AR in microglia offers an upstream therapeutic target [231]. The gene discussed is ADORA2A; the disease is Alzheimer disease.